HIV neutralizing antibody testing core
Neutralizing Antibody Core
['FUNDING_P01'] · DANA-FARBER CANCER INST · NIH-11307161
This project tests how well antibodies from vaccine recipients and people living with HIV can block different HIV strains to help design better vaccines.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11307161 on ClinicalTrials.gov |
What this research studies
This program runs a centralized lab that measures the ability of antibodies to neutralize diverse HIV viruses using standardized, validated assays. The team will test antibodies from mice given experimental mRNA immunogens and screen blood samples from people with HIV to find strong, MPER-specific neutralizing antibodies. When powerful patient-derived antibodies are found, researchers will clone and characterize them to compare with vaccine-elicited antibodies. Those head-to-head data will help guide improved immunogen design and vaccine delivery strategies.
Who could benefit from this research
Good fit: Ideal participants are people living with HIV or volunteers in HIV vaccine trials who can donate blood samples for antibody screening.
Not a fit: People seeking immediate changes to their HIV treatment or those unwilling to provide blood samples are unlikely to receive direct clinical benefit from this core's activities.
Why it matters
Potential benefit: If successful, this work could help speed development of HIV vaccines that teach the immune system to make broadly protective antibodies against many virus strains.
How similar studies have performed: Labs have previously identified broadly neutralizing HIV antibodies and used neutralization assays effectively, but reliably eliciting these antibodies by vaccination in people remains a major challenge.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SEAMAN, MICHAEL SCOTT — DANA-FARBER CANCER INST
- Study coordinator: SEAMAN, MICHAEL SCOTT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.